Dublin, Feb. 24, 2021 (GLOBE NEWSWIRE) -- The "Organoids and Spheroids Market Share, Size, Trends, Industry Analysis Report, By Type; By Application; By End-Use; By Regions; Segment Forecast, 2021-2028" report has been added to ResearchAndMarkets.com's offering.
The global organoids and spheroids market is expected to reach USD 2.47 billion by 2028, according to the study. This report gives a detailed insight into current market dynamics and provides analysis on future market growth.
The global organoids and spheroids industry is anticipated to grow, owing to the growing incidence of cancer, innovations in the tissue culture system, and continually failing organ transplantation surgeries. The compatibility between the donor and recipient should be cross-checked through artificial cell culture systems to save time and money.
The global market industry is fragmented based on type, application, end-use, and region. In terms of type, the market is segmented into organoids and spheroids. The application segment is further divided into developmental biology, personalized medicine, regenerative medicine, disease pathology studies, and drug toxicity & efficacy testing. In terms of end-use, the market is segmented into biotechnology and pharmaceutical industries, academic & research institutes, and hospitals and diagnostic centers.
Segment Highlights
- The spheroids market segment accounted for a major revenue share owing to its applicability in cancer research. The segment held over 50.0% of the global share in 2020. However, the organoid segment is expected to witness highest CAGR during the forecast period.
- Based on application, the development biology segment is projected to constitute almost half of the market in 2028. This is can be attributed for increased use of cell culture systems in the developmental biology.
- North America region is dominating the global organoids and spheroids industry, holding over one-third of the market share throughout the forecast period. The presence of key companies and increasing funding towards research are the factors responsible for its growth
Key Topics Covered:
1. Introduction
1.1. Report Description
1.1.1. Objectives of the Study
1.1.2. Market Scope
1.1.3. Assumptions
1.2. Stakeholders
2. Executive Summary
2.1. Market Highlights
3. Research Methodology
3.1. Overview
3.1.1. Data Mining
3.2. Data Sources
3.2.1. Primary Sources
3.2.2. Secondary Sources
4. Organoids and Spheroids Market Insights
4.1. Organoids and Spheroids - Industry snapshot
4.2. Organoids and Spheroids Market Dynamics
4.2.1. Drivers and Opportunities
4.2.1.1. Innovations in the cell culture
4.2.1.2. Promising investments
4.2.2. Restraints and Challenges
4.2.2.1. Stringent Regulatory Procedures
4.3. Porter's Five Forces Analysis
4.3.1. Bargaining Power of Suppliers (Moderate)
4.3.2. Threats of New Entrants: (Low)
4.3.3. Bargaining Power of Buyers (Moderate)
4.3.4. Threat of Substitute (Moderate)
4.3.5. Rivalry among existing firms (High)
4.4. PESTLE Analysis
4.5. Organoids and Spheroids Market Industry trends
5. Organoids and Spheroids Market Assessment by Type
5.1. Key Findings
5.2. Introduction
5.2.1. Global Organoids and Spheroids Market, By Type, 2016-2028 (USD Million)
5.3. Organoids
5.3.1. Global Organoids and Spheroids Market, by Organoids, by Region, 2016-2028 (USD Million)
5.3.2. By Type
5.3.2.1. Neural
5.3.2.1.1. Global Neural Organoids, by Region, 2016-2028 (USD Million)
5.3.2.2. Hepatic
5.3.2.2.1. Global Hepatic Organoids, by Region, 2016-2028 (USD Million)
5.3.2.3. Intestinal
5.3.2.3.1. Global Intestinal Organoids, by Region, 2016-2028 (USD Million)
5.3.2.4. Others
5.3.2.4.1. Global Other Organoids, by Region, 2016-2028 (USD Million)
5.3.3. By Method
5.3.3.1. General Submerged Method for Organoid Culture
5.3.3.1.1. Global General Submerged Method for Organoid Culture, by Region, 2016-2028 (USD Million)
5.3.3.2. Crypt Organoid Culture Techniques
5.3.3.2.1. Global Crypt Organoid Culture Techniques, by Region, 2016-2028 (USD Million)
5.3.3.3. Air Liquid Interface (ALI) Method for Organoid Culture
5.3.3.3.1. Air Liquid Interface (ALI) Method for Organoid Culture, by Region, 2016-2028 (USD Million)
5.3.3.4. Clonal Organoids from Lgr5+ Cells
5.3.3.4.1. Global Clonal Organoids from Lgr5+ Cells, by Region, 2016-2028 (USD Million)
5.3.4. By Source
5.3.4.1. Primary Tissues
5.3.4.1.1. Global Primary Tissues, by Region, 2016-2028 (USD Million)
5.3.4.2. Stem Cells
5.3.4.2.1. Global Stem Cells, by Region, 2016-2028 (USD Million)
5.4. Spheroids
5.4.1. Global Organoids and Spheroids Market, by Spheroids, by Region, 2016-2028 (USD Million)
5.4.2. By Type
5.4.2.1. Multicellular tumor spheroids (MCTS)
5.4.2.1.1. Global Multicellular tumor spheroids (MCTS), by Region, 2016-2028 (USD Million)
5.4.2.2. Neurospheres
5.4.2.2.1. Global Neurospheres, by Region, 2016-2028 (USD Million)
5.4.2.3. Mammospheres
5.4.2.3.1. Global Mammospheres, by Region, 2016-2028 (USD Million)
5.4.2.4. Hepatospheres
5.4.2.4.1. Global Hepatospheres, by Region, 2016-2028 (USD Million)
5.4.2.5. Embryoid Bodies
5.4.2.5.1. Global Embryoid Bodies, by Region, 2016-2028 (USD Million)
5.4.3. By Method
5.4.3.1. Micropatterned Plates
5.4.3.1.1. Global Micropatterned Plates, by Region, 2016-2028 (USD Million)
5.4.3.2. Low Cell Attachment Plates
5.4.3.2.1. Global Low Cell Attachment Plates, by Region, 2016-2028 (USD Million)
5.4.3.3. Hanging Drop Method
5.4.3.3.1. Global Hanging Drop Method, by Region, 2016-2028 (USD Million)
5.4.3.4. Others
5.4.3.4.1. Global Other Methods, by Region, 2016-2028 (USD Million)
5.4.4. By Source
5.4.4.1. Cell Line
5.4.4.1.1. Global Cell Line, by Region, 2016-2028 (USD Million)
5.4.4.2. Primary Cell
5.4.4.2.1. Global Primary Cell, by Region, 2016-2028 (USD Million)
5.4.4.3. iPSCs Derived Cells
5.4.4.3.1. Global iPSCs Derived Cells, by Region, 2016-2028 (USD Million)
6. Global Organoids and Spheroids Market, by Application
6.1. Key Findings
6.2. Introduction
6.2.1. Global Organoids and Spheroids Market, By Application, 2016-2028 (USD Million)
6.3. Developmental Biology
6.3.1. Global Organoids and Spheroids Market, by Developmental Biology, By Region, 2016-2028 (USD Million)
6.4. Personalized Medicine
6.4.1. Global Organoids and Spheroids Market, by Personalized Medicine, by Region, 2016-2028 (USD Million)
6.5. Regenerative Medicine
6.5.1. Global Organoids and Spheroids Market, by Regenerative Medicine, by Region, 2016-2028 (USD Million)
6.6. Disease Pathology Studies
6.6.1. Global Organoids and Spheroids Market, by Disease Pathology Studies, by Region, 2016-2028 (USD Million)
6.7. Drug Toxicity & Efficacy Testing
6.7.1. Global Organoids and Spheroids Market, by Drug Toxicity & Efficacy Testing, by Region, 2016-2028 (USD Million)
7. Global Organoids and Spheroids Market, by End-Use
7.1. Key Findings
7.2. Introduction
7.2.1. Global Organoids and Spheroids Market, By End-Use, 2016-2028 (USD Million)
7.3. Biotechnology & Pharmaceutical Industries
7.3.1. Global Organoids and Spheroids Market, by Biotechnology & Pharmaceutical Industries, By Region, 2016-2028 (USD Million)
7.4. Academic & Research Institutes
7.4.1. Global Organoids and Spheroids Market, by Academic & Research Institutes, by Region, 2016-2028 (USD Million)
7.5. Hospitals & Diagnostic Centers
7.5.1. Global Organoids and Spheroids Market, by Hospitals & Diagnostic Centers, by Region, 2016-2028 (USD Million)
8. Organoids and Spheroids Market Assessment by Geography
8.1. Key findings
8.2. Introduction
8.3. Organoids and Spheroids Market - North America
8.4. Organoids and Spheroids Market - Europe
8.5. Organoids and Spheroids Market - Asia-Pacific
8.6. Organoids and Spheroids Market - Middle East & Africa
8.7. Organoids and Spheroids Market - Latin America
9. Competitive Landscape
9.1. Expansion and Acquisition Analysis
9.1.1. Expansion
9.1.2. Acquisition
9.2. Partnerships/Collaborations/Agreements/Exhibitions
10. Company Profiles
10.1. 3D BioMatrix
10.1.1. Company Overview
10.1.2. Financial Performance
10.1.3. Product Benchmarking
10.1.4. Recent Developments
10.2. 3D Biotek LLC
10.2.1. Company Overview
10.2.2. Financial Performance
10.2.3. Product Benchmarking
10.2.4. Recent Developments
10.3. AMS Biotechnology (Europe) Limited
10.3.1. Company Overview
10.3.2. Financial Performance
10.3.3. Product Benchmarking
10.3.4. Recent Developments
10.4. Cellesce Ltd.
10.4.1. Company Overview
10.4.2. Financial Performance
10.4.3. Product Benchmarking
10.4.4. Recent Developments
10.5. Corning Incorporated
10.5.1. Company Overview
10.5.2. Financial Performance
10.5.3. Product Benchmarking
10.5.4. Recent Developments
10.6. Greiner Bio-One
10.6.1. Company Overview
10.6.2. Financial Performance
10.6.3. Product Benchmarking
10.6.4. Recent Developments
10.7. Hubrecht Organoid Technology (HUB)
10.7.1. Company Overview
10.7.2. Financial Performance
10.7.3. Product Benchmarking
10.7.4. Recent Developments
10.8. InSphero/Perkin Elmer
10.8.1. Company Overview
10.8.2. Financial Performance
10.8.3. Product Benchmarking
10.8.4. Recent Developments
10.9. Prellis Biologics
10.9.1. Company Overview
10.9.2. Financial Performance
10.9.3. Types/Product Benchmarking
10.9.4. Recent Developments
For more information about this report visit https://www.researchandmarkets.com/r/ieate